Full Answer
What are the price targets for Sanofi's shares?
9 brokers have issued 1 year price targets for Sanofi's shares. Their forecasts range from €80.00 to €124.00. On average, they anticipate Sanofi's stock price to reach €105.00 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price.
Is Sanofi SA’s (par) stock trading below its 52-week highs?
On Monday, Sanofi SA (SAN:PAR) closed at 89.36, -1.95% below its 52-week high of 91.14, set on Aug 23, 2021. Data delayed at least 15 minutes, as of Nov 22 2021 16:36 GMT. Sanofi SA is a healthcare company based in France.
Should you buy or sell Sanofi stock?
The consensus among Wall Street equities research analysts is that investors should "hold" Sanofi stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAN, but not buy additional shares or sell existing shares. View analyst ratings for Sanofi or view top-rated stocks.
What kind of company is Sanofi?
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmace
See more
Is Sanofi a good stock to buy now?
High-growth visibility from chronics, strong and debt-free balance sheet, sturdy dividends, and healthy cash position are the key positives for Sanofi, hence we retain our Buy recommendation on the stock with an unchanged PT of Rs 9,250.
Is Sanofi on NYSE?
Sanofi shares have been listed on Euronext Paris since May 25, 1999. They were also listed on the New York Stock Exchange in the form of ADSs (American Depositary Shares) between July 1, 2002 and December 31, 2018. Since January 2, 2019, Sanofi ADSs are listed on the Nasdaq Global Select Market (Nasdaq).
How much is Sanofi company worth?
120 billion U.S. dollarsSanofi S.A. had a total assets value of over 120 billion U.S. dollars in 2021, which is the highest asset value the company has had over the past decade.
Does Sanofi pay a dividend?
Sanofi pays a dividend 1 times a year. The payment month is May. The dividend calendar shows you for more than 1,000 dividend stocks in which month which company distributes its dividends. Plan your passive income for the whole year.
Is Sanofi large cap?
Market cap: $126.31 Billion As of July 2022 Sanofi has a market cap of $126.31 Billion. This makes Sanofi the world's 87th most valuable company by market cap according to our data.
Is Sanofi a Fortune 100?
Sanofi is #289 on the 2020 Fortune Global 500. The Fortune Global 500 is an annual ranking of the top corporations worldwide as measured by revenue.
How big is Sanofi?
SanofiFormerlySanofi-Synthélabo (1999–2004) Sanofi-Aventis (2004–2011)Total assets€120.24 billion (2021)Total equity€68.68 billion (2021)Number of employees95,442 (2021)SubsidiariesSanofi Pasteur Genzyme Shantha Biotechnics Chattem Ablynx Bioverativ14 more rows
What is Sanofi famous for?
Sanofi-Synthélabo is known for creating meningitis treatment, Menactra, diabetes treatment Lantus, colorectal cancer drug Eloxatin, and lung, prostate and breast cancer drug Taxorete.
Why Moderna Stock Is Falling Today
What happened Shares of Moderna (NASDAQ: MRNA) were down by 5.3% as of 1:25 p.m. ET Wednesday. The company announced a long-term collaboration with Thermo Fisher Scientific to manufacture messenger RNA (mRNA) vaccines.
Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot.
What is Sanofi valuation?
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales.
What is a key stat?
Key stats. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Originally, the company was established in 1973 and merged ...
When did Sanofi change its name?
It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication.
Is Sanofi a French company?
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Originally, the company was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, ...
French trade deficit in goods hits record level despite economic rebound
Finance minister Bruno Le Maire laments ‘black mark’ for economy as gap widens to €84.7bn
About the company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmace
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Headlines
Blume Capital Management, Inc. Buys T-Mobile US Inc, Sanofi SA, Vanguard Total Stock Market ... - Yahoo Finance
Sanofi (EPA:SAN) Frequently Asked Questions
9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sanofi stock.
